PROJECT

Projects

Environmental & Social Review Summary

Project Number

38104

Company Name

ESSEX BIO-TECHNOLOGY LIMITED

Date ESRS Disclosed

Jul 8, 2016

Country

China

Region

East Asia and the Pacific

Last Updated Date

Sep 27, 2024

Environmental Category

B - Limited

Status

Completed

Previous Events

Approved : Jun 23, 2016
Signed : Jul 6, 2016
Invested : Aug 2, 2016

Sector

Other Medical

Industry

Health, Education and Life Sciences

Department

Regional Industry - MAS Asia & Pac

Project Description

Founded in year 1990 and listed on the Hong Kong Growth Enterprise Market in 2001, Essex Bio-Technology Co Ltd. (“Essex” or “the company”) is a market leader engaged in the development, manufacturing and sales of biopharmaceutical drugs based on basic fibroblast growth factor (“bFGF”) technology. The principal activities of the company, which is headquartered in Zhuhai, Guangdong Province in China, are the manufacture and sale of biopharmaceutical products for the treatment and healing of surface wounds and eye wounds. Essex is also engaged in the research and development of new bFGF products as well as other ophthalmic pharmaceutical projects.

At present the company operates one manufacturing plant which was commissioned in 2014 and subsequently certified against the national requirements for good manufacturing practices for drugs (GMP, China Food and Drug Administration). The operational process of Essex includes; (i) production of pure bFGF (including adding of bFGF gene into express vector, cloning, activating, culturing, fermenting, bacterium breaking and purifying); and (ii) production of bFGF series drugs (dissolving and sterilizing of supplementary materials; mixing with bFGF, and bottling of products into sterilized bottles).

Essex has developed a strong drug distribution network in China with 39 regional sales offices (the company typically rents small offices in commercial centers for purposes of the sales office). In addition, Essex increases its product portfolio and revenue through obtaining distribution rights from other companies including Pfizer and Elektron. Essex is also actively seeking investment opportunities for technological advances or to increase its product pipeline.

IFC is considering a convertible loan of up to $ 19.3 million to be used for working capital financing of Essex. The proceeds of the loan will be used for general working capital requirements as well as to support strategic investments and capacity increase of the biopharmaceutical business.

Overview of IFC's Scope of Review

IFC’s environmental and social review of this project included:

- Discussions with the company’s management and personnel regarding environmental, health and safety (EHS) performance and labor practices;
- Site visit on March 31, 2016 to the Essex Bio facilities in Zhuhai;
- A review of EHS information provided in response to IFC’s environmental and social questionnaire and information obtained from follow-up discussions. More specifically reviewed documentation included; i) policies and procedures on environmental performance, occupational health and safety, emergency response and planning, results of air emissions and wastewater discharge monitoring; and ii) labor documentation (e.g., labor statistics, human resource (HR) policies and procedures).

E & S Project Categorization and Applicable Standard

Environmental and Social Mitigation Measures

Stakeholder Engagement

Broad Community Support

Environmental & Social Action Plan